World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
58
Citations
15654
World Ranking
3483
National Ranking
1617

Chantale Bernatchez publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Chantale Bernatchez sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 348 publications — 73rd percentile

73% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Chantale Bernatchez D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Chantale Bernatchez sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 58 D-Index — 30th percentile

30% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

Chantale Bernatchez is affiliated with The University of Texas MD Anderson Cancer Center in the United States. Their research primarily spans the fields of medicine, biochemistry, genetics and molecular biology, and immunology and microbiology. The scientist's work is extensively focused on oncology, immunology, molecular biology, cancer research, and pulmonary and respiratory medicine.

The research topics they frequently explore include cancer immunotherapy and biomarkers, CAR-T cell therapy research, immunotherapy and immune responses, cancer genomics and diagnostics, single-cell and spatial transcriptomics, immune cell function and interaction, and cancer research and treatments.

The list of frequent co-authors in their publications includes Cara Haymaker, Marie-Andrée Forget, Ignacio I. Wistuba, Michael A. Davies, and Alexandre Reuben.

They have published numerous papers in notable scientific venues. The most frequent publication venues are Cancer Research, Regular and Young Investigator Award Abstracts, Journal for ImmunoTherapy of Cancer, Clinical Cancer Research, and bioRxiv (Cold Spring Harbor Laboratory).

Recent significant papers by Chantale Bernatchez include:

  • Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial, 2021, Nature Medicine
  • Identification of bacteria-derived HLA-bound peptides in melanoma, 2021, Nature
  • Deep learning-based prediction of the T cell receptor-antigen binding specificity, 2021, Nature Machine Intelligence
  • Multimodal pooled Perturb-CITE-seq screens in patient models define mechanisms of cancer immune evasion, 2021, Nature Genetics
  • Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02), 2020, Cancer Discovery

Best Publications

  • Loss of PTEN Promotes Resistance to T Cell–Mediated Immunotherapy

    Weiyi Peng;Jie Qing Chen;Chengwen Liu;Shruti Malu

  • A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade

    Livnat Jerby-Arnon;Parin Shah;Michael S. Cuoco;Christopher Rodman

  • Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy

    Jianjun Gao;Lewis Zhichang Shi;Hao Zhao;Jianfeng Chen

  • Increased Tumor Glycolysis Characterizes Immune Resistance to Adoptive T Cell Therapy.

    Tina Cascone;Jodi A. McKenzie;Rina M. Mbofung;Simone Punt

  • Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial.

    Tina Cascone;William N. William;Annikka Weissferdt;Cheuk H. Leung

  • Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients

    Laszlo G. Radvanyi;Chantale Bernatchez;Minying Zhang;Patricia S. Fox

  • Combining Immune Checkpoint Blockade and Tumor-Specific Vaccine for Patients With Incurable Human Papillomavirus 16-Related Cancer: A Phase 2 Clinical Trial.

    Erminia Massarelli;William William;Faye Johnson;Merrill Kies

  • Identification of bacteria-derived HLA-bound peptides in melanoma

    Shelly Kalaora;Adi Nagler;Deborah Nejman;Michal Alon

  • Oncogenic BRAF(V600E) Promotes Stromal Cell-Mediated Immunosuppression Via Induction of Interleukin-1 in Melanoma

    Jahan S. Khalili;Shujuan Liu;Tania G. Rodríguez-Cruz;Mayra Whittington

  • Adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlook.

    Richard Wu;Marie Andrée Forget;Jessica Chacon;Jessica Chacon;Chantale Bernatchez

  • Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer.

    Jorge Blando;Anu Sharma;Maria Gisela Higa;Hao Zhao

  • Validation of multiplex immunofluorescence panels using multispectral microscopy for immune-profiling of formalin-fixed and paraffin-embedded human tumor tissues.

    Edwin R. Parra;Naohiro Uraoka;Mei Jiang;Pamela Cook

  • Deep learning-based prediction of the T cell receptor–antigen binding specificity

    Tianshi Lu;Ze Zhang;James Zhu;Yunguan Wang

  • Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02)

    Adi Diab;Nizar M. Tannir;Salah Eddine Bentebibel;Patrick Hwu

  • Multimodal pooled Perturb-CITE-seq screens in patient models define mechanisms of cancer immune evasion.

    Chris J. Frangieh;Johannes C. Melms;Pratiksha I. Thakore;Kathryn R. Geiger-Schuller;Kathryn R. Geiger-Schuller

  • A First-in-Human Study and Biomarker Analysis of NKTR-214, a Novel IL2Rβγ-Biased Cytokine, in Patients with Advanced or Metastatic Solid Tumors

    Salah Eddine Bentebibel;Michael E. Hurwitz;Chantale Bernatchez;Cara Haymaker

  • TCR Repertoire Intratumor Heterogeneity in Localized Lung Adenocarcinomas: An Association with Predicted Neoantigen Heterogeneity and Postsurgical Recurrence.

    Alexandre Reuben;Rachel Gittelman;Jianjun Gao;Jiexin Zhang

  • Comprehensive T cell repertoire characterization of non-small cell lung cancer

    Alexandre Reuben;Jiexin Zhang;Shin Heng Chiou;Rachel M. Gittelman

  • BRAFV600E Co-opts a Conserved MHC Class I Internalization Pathway to Diminish Antigen Presentation and CD8+ T-cell Recognition of Melanoma

    Sherille D. Bradley;Zeming Chen;Brenda Melendez;Amjad Talukder

  • Neoadjuvant nivolumab (N) or nivolumab plus ipilimumab (NI) for resectable non-small cell lung cancer (NSCLC): Clinical and correlative results from the NEOSTAR study.

    Tina Cascone;William Nassib William;Annikka Weissferdt;Heather Y. Lin

  • Effect of neoadjuvant chemotherapy on the immune microenvironment in non-small cell lung carcinomas as determined by multiplex immunofluorescence and image analysis approaches.

    Edwin R. Parra;Pamela Villalobos;Carmen Behrens;Mei Jiang

  • Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma

    Alexandre Reuben;Christine N. Spencer;Peter A. Prieto;Vancheswaran Gopalakrishnan

Frequent Co-Authors

Cara Haymaker
Cara Haymaker The University of Texas MD Anderson Cancer Center
Patrick Hwu
Patrick Hwu The University of Texas MD Anderson Cancer Center
Laszlo Radvanyi
Laszlo Radvanyi Ontario Institute for Cancer Research
Adi Diab
Adi Diab The University of Texas MD Anderson Cancer Center
Don L. Gibbons
Don L. Gibbons The University of Texas MD Anderson Cancer Center
John V. Heymach
John V. Heymach The University of Texas MD Anderson Cancer Center
Jennifer A. Wargo
Jennifer A. Wargo The University of Texas MD Anderson Cancer Center
Ignacio I. Wistuba
Ignacio I. Wistuba The University of Texas MD Anderson Cancer Center
Jason Roszik
Jason Roszik The University of Texas MD Anderson Cancer Center
Michael A. Davies
Michael A. Davies The University of Texas MD Anderson Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in Immunology, exploring related healthcare fields can open up diverse career opportunities. Nursing, especially at the advanced practice level, often intersects with immunological research and clinical care. Prospective students may find it helpful to look into programs that are accessible and streamlined. For example, the easiest np programs to get into offer pathways that balance quality education with admissions flexibility.

Specializing further, the mental health arena provides focused roles that benefit from immunological knowledge, such as psychiatric nursing. Online options like the top online pmhnp programs ensure students gain strong clinical experience while studying remotely. Affordability is equally crucial; discovering the cheapest psychiatric nurse practitioner programs can make advanced education more attainable.

Career outlook and earning potential also matter when planning your future. For example, understanding how much do dnp nurses make can help gauge the return on investment for nursing-focused advanced degrees related to immunology.

Best Scientists Citing Chantale Bernatchez

Trending Scientists

Recently Published Articles